09/29/2026 Notice Nippon Shokubai Enters into Strategic Collaboration with PURMX Therapeutics on Drug Delivery System (DDS) Material “Fol-Dab8”-Evaluating the Potential of Combining Fol-Dab8 with Naturally Occurring microRNA for Novel Oligonucleotide Therapeutics-
06/24/2025 NoticeTechnical Info Nippon Shokubai Plans to Expand Its GMP-Compliant Nucleic Acid Drug API Manufacturing Capacity Tenfold
